Research & Pipeline

At Aspire Pharma, innovation is central to our international growth strategy. From inception, our guiding principle has been to take a medicine, molecule, or device and enhance it – and that same commitment continues to guide our approach today.

Investment in research

Our continued investment in Research & Development (R&D) fuels a strong pipeline designed for both today’s performance and tomorrow’s growth. This means delivering improved presentations, formulations designed to enhance patient adherance, convenient dosing and new indications for trusted molecules.

Backed by our in-house expertise and a global network of partners, we are dedicated to bringing meaningful advances to clinical management, improved outcomes and making treatments more accessible for patients.

Investment in research

At Aspire Pharma, innovation is central to our international growth strategy.

From inception, our guiding principle has been to take a medicine, molecule, or device and enhance it – and that same commitment continues to guide our approach today.

Our continued investment in Research & Development (R&D) fuels a strong pipeline designed for both today’s performance and tomorrow’s growth. This means delivering improved presentations, patient-friendly formulations, convenient dosing and new indications for trusted molecules.

Backed by our in-house expertise and a global network of partners, we are dedicated to bringing meaningful advances to clinical management, improved outcomes and making treatments more accessible for patients.

“We are committed to adapting to a changing environment to bring innovative products to market, creating value and sustainability for the patients we serve.”

Dominic Beaumont
Head of Research & Development

Research and development pipeline

Aspire has a strong and forward-looking pipeline focused on repurposing molecules with established safety profiles. Our work focuses on developing new dosage forms, enhanced and hybrid formulations and technology-driven products that address unmet needs and unlock new therapeutic indications.

+25

Niche GenericsA wide range of targeted and specialised therapies.

+5

BrandsInnovative proprietary treatment covering a number of therapy areas.

+8

DermatologyAdditions to our established skin health ranges.

+4

OphthalmicBolstering our extensive vision care portfolio.

+3

Transformational ProjectsProgressing our development initiatives.

MAT-UK-COR-0032-2 | January 2026